Skip to main content
Top
Published in: Journal of Gastroenterology 5/2014

01-05-2014 | Original Article—Alimentary Tract

Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT)

Authors: Masahiro Tajika, Keitaro Matsuo, Hidemi Ito, Dai Chihara, Vikram Bhatia, Shinya Kondo, Tsutomu Tanaka, Nobumasa Mizuno, Kazuo Hara, Susumu Hijioka, Hiroshi Imaoka, Kazuya Matsumoto, Tsuneya Nakamura, Yasushi Yatabe, Kenji Yamao, Yasumasa Niwa

Published in: Journal of Gastroenterology | Issue 5/2014

Login to get access

Abstract

Background

It is controversial whether patients with gastric marginal zone lymphomas of mucosa associated lymphoid tissue (MALT) have higher risk of second malignancies. The aim of this study was to define the risk of second malignancies in these patients.

Methods

We analyzed prospective follow-up data of 146 consecutive patients with gastric MALT lymphoma treated at Aichi Cancer Center Hospital and compared the incidence of second malignancies with that in the general population. We calculated the standardized incidence ratio (SIR), using age- and sex-specific incidence rates from the Aichi Cancer Registry.

Results

The median follow-up period was 74 months. A total of 27 tumors occurred in 22 patients (15.1 %), including 19 solid tumors. Of these, nine tumors were detected concomitantly with, and 18 tumors following, the diagnosis of gastric MALT lymphoma. Four patients had two second malignancies each. For the entire group, the SIR of an additional malignancy was 3.39 (95 % confidence interval [CI] 2.11–4.66). An increased incidence of solid tumors (SIR 2.91 [1.60–4.22]) and hematologic malignancies (SIR 5.54 [1.70–9.38]) were seen. In addition, there was increased risk for development of second malignancies during follow up (SIR 2.26 [1.21–3.30]). Chemotherapy for treatment of MALT was an independent risk factor for second malignancies (age–sex adjusted hazard ratio 3.98 [1.47–10.79].

Conclusions

Compared with the general population, patients with gastric MALT lymphoma are at increased risk for second malignancies, including gastric cancer.
Literature
1.
go back to reference Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.PubMedCrossRef Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.PubMedCrossRef
2.
go back to reference Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.PubMedCrossRef Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.PubMedCrossRef
3.
go back to reference Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97:1345–53.PubMedCrossRef Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst. 2005;97:1345–53.PubMedCrossRef
4.
go back to reference Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23:8018–24.PubMedCrossRef Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol. 2005;23:8018–24.PubMedCrossRef
5.
go back to reference Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, et al. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study. Dig Liver Dis. 2009;41:467–73.PubMedCrossRef Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, et al. Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: an Italian, multicentre study. Dig Liver Dis. 2009;41:467–73.PubMedCrossRef
6.
go back to reference Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20:1086–93.PubMedCrossRef Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. Ann Oncol. 2009;20:1086–93.PubMedCrossRef
7.
go back to reference Ono S, Kato M, Takagi K, Kodaira J, Kubota K, Matsuno Y, et al. Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol. 2010;25:804–9.PubMedCrossRef Ono S, Kato M, Takagi K, Kodaira J, Kubota K, Matsuno Y, et al. Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer. J Gastroenterol Hepatol. 2010;25:804–9.PubMedCrossRef
8.
go back to reference Zucca E, Pinotti G, Roggero E, Comi MA, Pascarella A, Capella C, et al. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Ann Oncol. 1995;6:726–8.PubMed Zucca E, Pinotti G, Roggero E, Comi MA, Pascarella A, Capella C, et al. High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma. Ann Oncol. 1995;6:726–8.PubMed
9.
go back to reference Luppi M, Longo G, Ferrari MG, Ferrara L, Marasca R, Barozzi P, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol. 1996;94:373–5.PubMedCrossRef Luppi M, Longo G, Ferrari MG, Ferrara L, Marasca R, Barozzi P, et al. Additional neoplasms and HCV infection in low-grade lymphoma of MALT type. Br J Haematol. 1996;94:373–5.PubMedCrossRef
10.
go back to reference Hamaloglu E, Topaloglu S, Ozdemir A, Ozenc A. Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: a review of the literature. World J Gastroenterol. 2006;12:3564–74.PubMed Hamaloglu E, Topaloglu S, Ozdemir A, Ozenc A. Synchronous and metachronous occurrence of gastric adenocarcinoma and gastric lymphoma: a review of the literature. World J Gastroenterol. 2006;12:3564–74.PubMed
11.
go back to reference Oka K, Nagayama R, Yonekawa N, Nihei T, Sando N, Yatabe Y, et al. Concurrent gastric MALT and Hodgkin lymphoma: a case report. Int J Surg Pathol. 2012;20:201–4.PubMed Oka K, Nagayama R, Yonekawa N, Nihei T, Sando N, Yatabe Y, et al. Concurrent gastric MALT and Hodgkin lymphoma: a case report. Int J Surg Pathol. 2012;20:201–4.PubMed
12.
go back to reference Terada T. One patient with double lymphomas: simultaneous gastric MALT lymphoma and ileal diffuse large B-cell lymphoma. Int J Clin Exp Pathol. 2012;5:260–3.PubMedCentralPubMed Terada T. One patient with double lymphomas: simultaneous gastric MALT lymphoma and ileal diffuse large B-cell lymphoma. Int J Clin Exp Pathol. 2012;5:260–3.PubMedCentralPubMed
13.
go back to reference Capelle LG, de Vries AC, Looman CW, van Blankenstein M, van Grieken NC, Casparie MK, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44:2470–6.PubMedCrossRef Capelle LG, de Vries AC, Looman CW, van Blankenstein M, van Grieken NC, Casparie MK, et al. Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44:2470–6.PubMedCrossRef
14.
go back to reference Au WY, Gascoyne RD, Le N, Viswanatha DS, Klasa RJ, Gallagher R, et al. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 1999;10:317–21.PubMedCrossRef Au WY, Gascoyne RD, Le N, Viswanatha DS, Klasa RJ, Gallagher R, et al. Incidence of second neoplasms in patients with MALT lymphoma: no increase in risk above the background population. Ann Oncol. 1999;10:317–21.PubMedCrossRef
15.
go back to reference Montalbàn C, Castrillo JM, López-Abente G, Abraira V, Serrano M, Bellas C, et al. Other cancers in patients with gastric MALT lymphoma. Leuk Lymphoma. 1999;33:161–8.PubMed Montalbàn C, Castrillo JM, López-Abente G, Abraira V, Serrano M, Bellas C, et al. Other cancers in patients with gastric MALT lymphoma. Leuk Lymphoma. 1999;33:161–8.PubMed
16.
go back to reference Cammarota G, Larocca LM, D’Ugo D, Persiani R, Cianci R, Nocente R, et al. Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with H. pylori infection. Could the two neoplasms share a common pathogenesis? Hepatogastroenterology. 2001;48:104–6.PubMed Cammarota G, Larocca LM, D’Ugo D, Persiani R, Cianci R, Nocente R, et al. Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with H. pylori infection. Could the two neoplasms share a common pathogenesis? Hepatogastroenterology. 2001;48:104–6.PubMed
17.
go back to reference Chan AO, Chu KM, Yuen ST, Leung SY, Lam SK, Wong J. Synchronous gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma in association with Helicobacter pylori infection: comparing reported cases between the East and West. Am J Gastroenterol. 2001;96:1922–4.PubMedCrossRef Chan AO, Chu KM, Yuen ST, Leung SY, Lam SK, Wong J. Synchronous gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma in association with Helicobacter pylori infection: comparing reported cases between the East and West. Am J Gastroenterol. 2001;96:1922–4.PubMedCrossRef
18.
go back to reference Ito H, Inoue M, Shibata K, Tajima K. Estimation of cancer incidences in Aichi prefecture: use of a model area with good quality registry data. Asian Pac J Cancer Prev. 2004;5:320–7.PubMed Ito H, Inoue M, Shibata K, Tajima K. Estimation of cancer incidences in Aichi prefecture: use of a model area with good quality registry data. Asian Pac J Cancer Prev. 2004;5:320–7.PubMed
19.
go back to reference Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–49.PubMed
20.
go back to reference Rohatiner A, d’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.PubMedCrossRef Rohatiner A, d’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.PubMedCrossRef
21.
go back to reference Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann Oncol. 2011;22:1845–58.PubMedCrossRef Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis. Ann Oncol. 2011;22:1845–58.PubMedCrossRef
22.
go back to reference Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J Clin Oncol. 2006;24:1568–74.PubMedCrossRef Mudie NY, Swerdlow AJ, Higgins CD, Smith P, Qiao Z, Hancock BW, et al. Risk of second malignancy after non-Hodgkin’s lymphoma: a British Cohort Study. J Clin Oncol. 2006;24:1568–74.PubMedCrossRef
23.
go back to reference Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1993;85:1932–7.PubMedCrossRef Travis LB, Curtis RE, Glimelius B, Holowaty E, Van Leeuwen FE, Lynch CF, et al. Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst. 1993;85:1932–7.PubMedCrossRef
24.
go back to reference Shinmura K, Sugimura H, Naito Y, Shields PG, Kino I. Frequent co-occurrence of mutator phenotype in synchronous, independent multiple cancers of the stomach. Carcinogenesis. 1995;16:2989–93.PubMedCrossRef Shinmura K, Sugimura H, Naito Y, Shields PG, Kino I. Frequent co-occurrence of mutator phenotype in synchronous, independent multiple cancers of the stomach. Carcinogenesis. 1995;16:2989–93.PubMedCrossRef
25.
go back to reference Levy V, Miller C, Koeffler HP, Said JW. p53 in lymphomas of mucosal-associated lymphoid tissues. Mod Pathol. 1996;9:245–8.PubMed Levy V, Miller C, Koeffler HP, Said JW. p53 in lymphomas of mucosal-associated lymphoid tissues. Mod Pathol. 1996;9:245–8.PubMed
26.
go back to reference Neumeister P, Hoefler G, Beham-Schmid C, Schmidt H, Apfelbeck U, Schaider H, et al. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology. 1997;112:1871–5.PubMedCrossRef Neumeister P, Hoefler G, Beham-Schmid C, Schmidt H, Apfelbeck U, Schaider H, et al. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology. 1997;112:1871–5.PubMedCrossRef
27.
go back to reference Calvert R, Randerson J, Evans P, Cawkwell L, Lewis F, Dixon MF, et al. Genetic abnormalities during transition from Helicobacter-pylori-associated gastritis to low-grade MALToma. Lancet. 1995;345:26–7.PubMedCrossRef Calvert R, Randerson J, Evans P, Cawkwell L, Lewis F, Dixon MF, et al. Genetic abnormalities during transition from Helicobacter-pylori-associated gastritis to low-grade MALToma. Lancet. 1995;345:26–7.PubMedCrossRef
28.
go back to reference Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood. 1995;85:2000–4.PubMed Wotherspoon AC, Finn TM, Isaacson PG. Trisomy 3 in low-grade B-cell lymphomas of mucosa-associated lymphoid tissue. Blood. 1995;85:2000–4.PubMed
29.
go back to reference Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–31.PubMedCrossRef Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–31.PubMedCrossRef
30.
go back to reference Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267–71.PubMedCrossRef Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267–71.PubMedCrossRef
31.
go back to reference Witherell HL, Hansen S, Jellum E, Orentreich N, Vogelman JH, Parsonnet J. Risk for gastric lymphoma in persons with CagA+ and CagA− Helicobacter pylori infection. J Infect Dis. 1997;176:1641–4.PubMedCrossRef Witherell HL, Hansen S, Jellum E, Orentreich N, Vogelman JH, Parsonnet J. Risk for gastric lymphoma in persons with CagA+ and CagAHelicobacter pylori infection. J Infect Dis. 1997;176:1641–4.PubMedCrossRef
32.
go back to reference Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;40:297–301.PubMedCentralPubMed Parsonnet J, Friedman GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection. Gut. 1997;40:297–301.PubMedCentralPubMed
33.
go back to reference Endo M, Habu H. Clinical studies of early gastric cancer. Hepatogastroenterology. 1990;37:408–10.PubMed Endo M, Habu H. Clinical studies of early gastric cancer. Hepatogastroenterology. 1990;37:408–10.PubMed
34.
go back to reference Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric caners after endoscopic mucosal resection. Endoscopy. 2005;37:990–3.PubMedCrossRef Nasu J, Doi T, Endo H, Nishina T, Hirasaki S, Hyodo I. Characteristics of metachronous multiple early gastric caners after endoscopic mucosal resection. Endoscopy. 2005;37:990–3.PubMedCrossRef
35.
go back to reference Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology. 2005;128:1579–605.PubMedCrossRef Farinha P, Gascoyne RD. Helicobacter pylori and MALT lymphoma. Gastroenterology. 2005;128:1579–605.PubMedCrossRef
36.
go back to reference Ye H, Liu H, Attygalle A, Wotherspoon AC, Nicholson AG, Charlotte F, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood. 2003;102:1012–8.PubMedCrossRef Ye H, Liu H, Attygalle A, Wotherspoon AC, Nicholson AG, Charlotte F, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood. 2003;102:1012–8.PubMedCrossRef
37.
go back to reference Inagaki H, Nakamura T, Li C, Sugiyama T, Asaka M, Kodaira J, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol. 2004;28:1560–7.PubMedCrossRef Inagaki H, Nakamura T, Li C, Sugiyama T, Asaka M, Kodaira J, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol. 2004;28:1560–7.PubMedCrossRef
38.
go back to reference Nakamura T, Seto M, Tajika M, Kawai H, Yokoi T, Yatabe Y, et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am J Gastroenterol. 2008;103:62–70.PubMedCrossRef Nakamura T, Seto M, Tajika M, Kawai H, Yokoi T, Yatabe Y, et al. Clinical features and prognosis of gastric MALT lymphoma with special reference to responsiveness to H. pylori eradication and API2-MALT1 status. Am J Gastroenterol. 2008;103:62–70.PubMedCrossRef
39.
go back to reference Copie-Bergman C, Locher C, Levy M, Chaumette MT, Haioun C, Delfau-Larue MH, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol. 2005;16:1232–6.PubMedCrossRef Copie-Bergman C, Locher C, Levy M, Chaumette MT, Haioun C, Delfau-Larue MH, et al. Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma? Ann Oncol. 2005;16:1232–6.PubMedCrossRef
40.
go back to reference Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer. 2001;85:997–1005.PubMedCentralPubMedCrossRef Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a search for common mechanisms. Br J Cancer. 2001;85:997–1005.PubMedCentralPubMedCrossRef
41.
go back to reference Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer. 1990;66:80–8.PubMedCrossRef Lavey RS, Eby NL, Prosnitz LR. Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomas. Cancer. 1990;66:80–8.PubMedCrossRef
42.
go back to reference Lishner M, Slingerland J, Barr J, Panzarella T, Degendorfer P, Sutcliffe S. Second malignant neoplasms in patients with non Hodgkin’s lymphoma. Hematol Oncol. 1991;9:169–79.PubMedCrossRef Lishner M, Slingerland J, Barr J, Panzarella T, Degendorfer P, Sutcliffe S. Second malignant neoplasms in patients with non Hodgkin’s lymphoma. Hematol Oncol. 1991;9:169–79.PubMedCrossRef
43.
go back to reference André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222–8.PubMedCrossRef André M, Mounier N, Leleu X, Sonet A, Brice P, Henry-Amar M, et al. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. Blood. 2004;103:1222–8.PubMedCrossRef
44.
go back to reference Zorlu AF, Atahan IL, Gedikoglu G, Ruacan S, Sayek I, Tekuzman G. Does gastric adenocarcinoma develop after the treatment of gastric lymphoma? J Surg Oncol. 1993;54:126–31.PubMedCrossRef Zorlu AF, Atahan IL, Gedikoglu G, Ruacan S, Sayek I, Tekuzman G. Does gastric adenocarcinoma develop after the treatment of gastric lymphoma? J Surg Oncol. 1993;54:126–31.PubMedCrossRef
45.
go back to reference Pectasides D, Arapantoni-Dadiotou P, Louloudaki D, Varthalitis I, Dimitriades M, Athanassiou A. Gastric adenocarcinoma after gastric lymphoma: the role of chemoradiotherapy. Ann Oncol. 1993;4:256–7.PubMed Pectasides D, Arapantoni-Dadiotou P, Louloudaki D, Varthalitis I, Dimitriades M, Athanassiou A. Gastric adenocarcinoma after gastric lymphoma: the role of chemoradiotherapy. Ann Oncol. 1993;4:256–7.PubMed
46.
go back to reference Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, et al. Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy. Clin Cancer Res. 2007;13:182–6.PubMedCrossRef Arcaini L, Burcheri S, Rossi A, Pascutto C, Passamonti F, Brusamolino E, et al. Risk of second cancer in nongastric marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue: a population-based study from northern Italy. Clin Cancer Res. 2007;13:182–6.PubMedCrossRef
47.
go back to reference Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11:285–91.PubMedCrossRef Arcaini L, Burcheri S, Rossi A, Passamonti F, Paulli M, Boveri E, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist. 2006;11:285–91.PubMedCrossRef
Metadata
Title
Risk of second malignancies in patients with gastric marginal zone lymphomas of mucosa associate lymphoid tissue (MALT)
Authors
Masahiro Tajika
Keitaro Matsuo
Hidemi Ito
Dai Chihara
Vikram Bhatia
Shinya Kondo
Tsutomu Tanaka
Nobumasa Mizuno
Kazuo Hara
Susumu Hijioka
Hiroshi Imaoka
Kazuya Matsumoto
Tsuneya Nakamura
Yasushi Yatabe
Kenji Yamao
Yasumasa Niwa
Publication date
01-05-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-013-0844-8

Other articles of this Issue 5/2014

Journal of Gastroenterology 5/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.